Dr Rappo is Senior Director of clinical development at BiomX, a biotech company developing phage cocktails designed to target and destroy harmful bacteria. Prior to joining BiomX in 2020, Dr Rappo worked on the clinical development of dalbavancin and other anti-infectives at Durata Therapeutics, Actavis and Allergan. As an adult infectious disease physician, she focuses on developing safer and more effective treatment options for difficult to treat infections.
Archives: Speakers
Ashley Sullivan
Ashley Sullivan has more than 13 years’ experience in clinical research. As Director of Study Start-up at Allucent, Ashley is responsible for leading, developing and coordinating activities and staff within Study Start-up & Site Intelligence and developing and implementing business strategies to ensure quality and timely performance of all start-up activities. She guided the overhaul and implementation of a specialized SSU module within CTMS allowing for improved metric tracking and reporting. Ashley also focuses on collaborating across functional areas to ensure a smooth working relationship between Study Start-up and other departments for overall successful trial conduct and delivery for clients.
Krishna Allamneni
With over two decades of pharmaceutical industry experience, I excel in strategically navigating benefit-risk profiles for diverse therapeutic modalities, from monoclonal antibodies to small molecules, and for various therapeutic areas including Oncology, Hematology, CNS, Infectious, Autoimmune, Diabetes, Liver & Metabolism, to name a few. My leadership style prioritizes people, fostering trust and collaboration at all levels. I am a forward-thinking leader in R&D strategy and tactical planning, and a highly regarded operational manager for key R&D functions. My Biopharma R&D expertise includes early development leadership of about 25 IND/IMPD programs, 7 NDA/MAA approvals, and a track record of efficiently developing therapeutic candidates. I have had impactful global regulatory interactions with FDA, MHRA, BfArM, ANSM, PMDA, Health Canada, TGA etc. during clinical development, partnership, and commercialization. Currently, I’m the Chief Development Officer at Concarlo Therapeutics, Inc., driving early-stage “pipeline in a target” towards clinical development. Previously, at Turning Point Therapeutics, Inc., I led a lean, outsourced DevSci function, contributing to a $2B+ valuation and a $200M follow-on offering. In addition, my background spans leadership roles at Jazz Pharmaceuticals, Inc., NGM Biopharmaceuticals, Inc., Genentech, Celera Genomics and other industry leaders. My education includes a Ph.D. in Pharmacology/Toxicology and certification from the American Board of Toxicology. I volunteer for California Life Sciences as their Scientific Advisor on FAST Kansai program. I am a member of the WIB Board Room Ready 2023 cohort. As a dedicated member of professional organizations like the American College of Toxicology and Society of Toxicology, I actively contribute to advancing the field. I thrive in fast-paced environments, leveraging a strategic mindset and a biotech approach to achieve results.
Jessica Hatheway
Sebastian Gabler
Bernd Schopp
Anna Mason
Beatrice Setnik
Kenton Kavitz
Dr Kenton Zavitz has over 25 years of biotechnology and pharmaceutical experience with involvement in all aspects of the industry from drug discovery and clinical development through to pre-commercialization. Prior to joining Cambridge Cognition, Kenton served as Chief Scientific Officer for New Mexico-based biotech Zocere Inc. where he worked on developing a neuroprotectant drug designed to combat brain injury resulting from stroke. He has served on the Scientific Advisory Board for Exonate Limited, a start-up founded in 2013 at the University of Nottingham. From 1998 to 2012, Kenton worked at Myriad Pharmaceuticals, Inc. in Salt Lake City and served in a variety of roles including Senior Director of Clinical Affairs, Chief Scientist of the tarenflurbil clinical development program (an investigational drug for the treatment of Alzheimer’s disease, developed through Phase 3), Director of Neurodegeneration Therapeutics Discovery and Director of Strategic In-licensing and Scientific Evaluation. Kenton received his PhD in Biochemistry and Molecular Biology from The Sloan-Kettering Division of the Weill Cornell Graduate School of Medical Sciences in New York City. He was a Postdoctoral Fellow at the UCLA School of Medicine and was awarded fellowships from the Leukemia Society of America and the Jane Coffin Childs Memorial Fund for Medical Research.
David Berry
Dave Berry is a Principal Data Scientist at PPD/Thermo Fisher Scientific, where he leads the development of advanced machine learning models to optimize clinical trial operations. With a diverse background in data science, computational biology, and bioinformatics, Dave has a proven track record of innovating at the intersection of life science and artificial intelligence. His work focuses on leveraging generative AI, large language models, and machine learning to drive operational efficiency and transformative solutions in clinical research.